CORT
Corcept Therapeutics Incorporated
Stock
$116.23+2.20 (+1.93%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $110M | $142M | $198M | $127M | $120M | $168M | $152M | $136M | $116M | $61M | $18M | $3.1M | −$27M | −$37M | −$36M | −$27M | −$22M | −$18M |
| Capital expenditures | $2.8M | $211K | $2.2M | $139K | $413K | $469K | $1.2M | $1.1M | $298K | $419K | $194K | $17K | $174K | $127K | $151K | $25K | — | — |
| Free cash flow | $107M | $142M | $196M | $127M | $120M | $167M | $151M | $135M | $115M | $61M | $18M | $3.1M | −$28M | −$37M | −$36M | −$27M | — | — |
| Stock-based compensation | $96M | $85M | $61M | $49M | $42M | $43M | $34M | $29M | $24M | $13M | $7.1M | $6.0M | $5.2M | $5.2M | $5.3M | $3.4M | $2.1M | $1.8M |
| Buybacks | $42M | $173M | $16M | $0 | $0 | — | $9.9M | $31M | $24M | $0 | $0 | — | — | — | — | — | — | — |
| Dividends per share | — | — | — | — | — | — | — | — | — | — | — | — | — | $0.00 | — | — | — | — |
| Free cash flow margin | 12.9% | 18.6% | 29.1% | 26.2% | 29.8% | 45.7% | 42.6% | 44.1% | 45.9% | 38.0% | 22.4% | — | — | — | — | — | — | — |